Strength and Presentation Differences in Biosimilarity: Controversies in Regulatory Approaches

The presence of limited information with no detail in biosimilar guidelines major regulatory agencies, together findings clues suggestive possible controversies between their approaches made the issue strength one most curious areas for sponsors seeking authority answers questions regarding similarity proposed biosimilars reference products.